---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-23-000109"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T20:06:46.286948+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# JNJ completes Laminar acquisition for $400M upfront; cuts FY2023 adjusted EPS guidance by $0.17

## Summary
- Upfront payment of $400M (subject to adjustments) plus potential clinical/regulatory milestone payments.
- Laminar's LAAX device uses rotational motion to eliminate left atrial appendage; FDA approved U.S. pivotal study starting in early 2024.
- FY2023 adjusted operational EPS guidance revised to $9.85-$9.91; reported to $9.90-$9.96, reflecting $0.17 IPR&D charge.
- Acquisition expected to reduce FY2024 EPS by approximately $0.15.
- Biosense Webster (JNJ MedTech) will integrate Laminar; targets ~38M AFib patients worldwide.

## SEC filing metadata
- accession: 0000200406-23-000109
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040623000109/0000200406-23-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040623000109/jnj-20231130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-23-000109
- JSON: https://secwatch.observer/filing/0000200406-23-000109.json
- Plain text: https://secwatch.observer/filing/0000200406-23-000109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.